Anti-Obesity Drugs Market by Drug Type, Mechanism of Action

KEY MARKET STATISTICS
Base Year [2023]	USD 3.83 billion
Estimated Year [2024]	USD 4.09 billion
Forecast Year [2030]	USD 6.10 billion
CAGR (%)	6.86%

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Obesity Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Obesity Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co. Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus Inc..

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Over-The-Counter Drugs
- Prescription Drugs
Mechanism of Action
- Centrally Acting Drugs
- Peripherally Acting Drugs
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-Obesity Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Obesity Drugs Market?

3. What are the technology trends and regulatory frameworks in the Anti-Obesity Drugs Market?

4. What is the market share of the leading vendors in the Anti-Obesity Drugs Market?

5. Which modes and strategic moves are suitable for entering the Anti-Obesity Drugs Market?

Product Code: MRR-434CCDA05192

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Anti-Obesity Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising burden of obesity and related chronic diseases
  - 5.1.1.2. Rapid consumption of unhealthy fast-foods and ready meals
  - 5.1.1.3. Increasing inclination towards health & fitness
- 5.1.2. Restraints
  - 5.1.2.1. Side-effects associated with drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Growing awareness among people with collaborative strategies
  - 5.1.3.2. Recent advancements in drug treatment of obesity
- 5.1.4. Challenges
  - 5.1.4.1. Availability of alternative treatment options in market
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Anti-Obesity Drugs Market, by Drug Type

6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Drugs

7. Anti-Obesity Drugs Market, by Mechanism of Action

7.1. Introduction
7.2. Centrally Acting Drugs
7.3. Peripherally Acting Drugs

8. Americas Anti-Obesity Drugs Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Anti-Obesity Drugs Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Drugs Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. Bayer AG
- 12.1.2. Boehringer Ingelheim International GmbH
- 12.1.3. Bristol-Myers Squibb Company
- 12.1.4. Currax Pharmaceuticals LLC
- 12.1.5. Eisai Co. Ltd
- 12.1.6. F. Hoffmann-La Roche AG
- 12.1.7. GlaxoSmithKline PLC
- 12.1.8. Merck & Co. Inc.
- 12.1.9. Norgine BV
- 12.1.10. Novo Nordisk AS
- 12.1.11. Pfizer Inc.
- 12.1.12. Rhythm Pharmaceuticals, Inc.
- 12.1.13. SHIONOGI & Co., Ltd.
- 12.1.14. Takeda Pharmaceutical Company Limited
- 12.1.15. Vivus Inc.
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing